Skip to main content
212 search results for:

Finerenone 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 18-04-2024 | Finerenone | Online First

    Finerenone in type 2 diabetic and albuminuric renal disease patients: three case reports

  2. Open Access 01-12-2024 | Finerenone | OriginalPaper

    Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies

    High levels of protein in the urine are a common symptom in children with kidney disease and can lead to progressive kidney damage. The increased level of protein in the urine is a risk factor that can be targeted by drugs; therefore, drugs that …

  3. 22-02-2024 | Finerenone | Online First

    Comment on “Effect of finerenone on cardiovascular events in kidney disease and/or diabetes”

  4. Open Access 01-12-2024 | Finerenone | OriginalPaper

    Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis

    Over the past few decades, the prevalence of type 2 diabetes mellitus (T2DM) has risen dramatically worldwide, and approximately 537 million adults are living with diabetes [ 1 ], resulting in an elevated risk of cardiovascular and renal diseases.

  5. 17-10-2023 | Finerenone | ReviewPaper

    The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances

    Chronic kidney disease (CKD) is a widespread and progressive disease characterized by a gradual loss of kidney function [ 1 , 2 ]. It affects millions of individuals worldwide and poses a significant burden on healthcare systems globally, with …

  6. Open Access 24-10-2023 | Finerenone | ReviewPaper

    The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone

    Finerenone, a selective and nonsteroidal antagonist of the mineralocorticoid receptor, has received regulatory approval with the indication of cardiorenal protection in patients with chronic kidney disease associated with type 2 diabetes. It is …

  7. Open Access 01-12-2023 | Finerenone | OriginalPaper

    Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus

    Diabetes is a growing global disease, with more than 500 million people suffering from it according to statistics [ 1 ]. Among these patients, even without vascular disease and other cardiac abnormalities, heart failure develops, called diabetic …

  8. Open Access 29-06-2023 | Diabetes-associated Diseases | Review

    The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction

    An overview of HFpEF pathophysiology and the potential therapeutic role of finerenone – a non-steroidal mineralocorticoid receptor antagonist approved for patients with chronic kidney disease and type 2 diabetes.

  9. Open Access 01-12-2023 | Finerenone | OriginalPaper

    Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

    Type 2 diabetes (T2D) affects over one million people in the Netherlands in total [ 1 ]. T2D can lead to vascular and neuropathic damage which increases the risk of chronic conditions, including chronic kidney disease (CKD) [ 2 ]. National data …

  10. Open Access 01-12-2023 | Finerenone | OriginalPaper

    An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria

    The prevalence of chronic kidney disease (CKD) has increased in recent decades alongside an increase in diabetes and hypertension, the main drivers of CKD [ 1 ]. Kidney disease, attributable to diabetes mellitus (diabetic kidney disease; DKD), is …

  11. Open Access 01-12-2023 | Finerenone | OriginalPaper

    Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)

    Type 2 diabetes (T2D) is a major cause of chronic kidney disease (CKD) and end-stage renal disease, which pose significant economic and medical burden on worldwide health care [ 1 ]. T2D and CKD are closely and synergistically associated with a …

  12. 22-10-2022 | Spironolactone | ReviewPaper

    The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management

    The implication of mineralocorticoid receptor (MR) overactivation in the development of cardiorenal syndrome is well documented [ 1 – 4 ]. On a structural and functional level, the MR is a ligand-activated nuclear transcription factor expressed on …

  13. Open Access 23-06-2022 | Spironolactone | ReviewPaper

    Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist

    Overactivation of the renin–angiotensin–aldosterone system (RAAS) has been shown to be pathologic in heart failure and albuminuric chronic kidney disease (CKD), triggering pro-inflammatory and pro-fibrotic cellular pathways. The standard of care …

  14. 04-08-2022 | Eplerenon | ReviewPaper

    Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure

    Mineralocorticoids such as aldosterone, deoxycorticosterone, and cortisol exert cellular responses through binding to mineralocorticoid receptors (MRs). These receptors are members of the nuclear receptor superfamily and function as …

  15. 01-10-2021 | Finerenone | ReviewPaper

    Finerenone: First Approval

    Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart …

  16. 22-06-2023 | Type 2 Diabetes | News | Article

    Finerenone modifies CKD-associated CV risk in albuminuric type 2 diabetes

    Finerenone modifies the risk for chronic kidney disease associated cardiovascular events in patients with type 2 diabetes and moderate-to-severe albuminuria, FIDELITY study findings indicate.

  17. Open Access 01-12-2022 | Stroke | ReviewPaper

    Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease

    As the most common sustained arrhythmia, atrial fibrillation (AF) not only increases the risk of stroke and heart failure, but also leads to the cerebrovascular death [ 1 , 2 ]. It is generally acknowledged that both chronic kidney disease (CKD) …

  18. Open Access 01-12-2022 | Dapagliflozin | OriginalPaper

    Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

    As the prevalence of diabetes increases over the recent years, approximately 536.6 million are diagnosed with Dabetes Mellitus (DM). It is estimated that by the year of 2045, at least 783.2 million adults will be affected by diabetes [ 1 ].

  19. Open Access 01-07-2021 | Spironolactone | ReviewPaper

    The Role of Finerenone in the Management of Diabetic Nephropathy

    Diabetic nephropathy (DN) is the leading cause of chronic kidney disease. Even though mineralocorticoid receptor antagonists (MRA) induce incremental reductions in urine albumin excretion when added to angiotensin-converting enzyme inhibitors or …

  20. 26-12-2022 | Finerenone | OriginalPaper

    Effect of finerenone on cardiovascular events in kidney disease and/or diabetes: a meta analysis of randomized control trials

    Finerenone is a non-steroidal corticosteroid receptor antagonist [ 1 , 2 ], which is mainly used in adult patients with diabetes mellitus related chronic kidney disease and can effectively alleviate the decreased glomerular filtration rate and the …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.